Premier Pharmacy Labs Recalls Products Due to Sterility Concerns
Premier Pharmacy Labs is voluntarily recalling multiple products because of the potential lack of sterility assurance.
Premier Pharmacy Labs announced on April 11, 2018 that it was voluntarily recalling products because of a potential lack of sterility assurance. The recall was initiated after the company detected microbial contamination during routine testing of subsequent unreleased product lots. An interaction between the product syringe and tamper-evident container closure was found. The company stated in a press release that this interaction may result in the potential introduction of microorganisms.
While the company has not yet received any complaints about adverse events, it warns that use of “non-sterile injection products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, significant morbidity (permanent organ damage), or a fatal outcome.”
Products affected by the recall, which were distributed nationwide to hospital pharmacies, clinics, and healthcare facilities, include the following:
- Morphine Sulfate (Single Dose Syringe) 2mg/mL Preservative Free Injection
- Morphine Sulfate (Single Dose Syringe) 4mg/mL Preservative Free Injection
- Hydromorphone HCL (Single Dose Syringe) 1mg/mL Preservative Free Injection
- Neostigmine Methylsulfate (Single Dose Syringe) 1mg/mL Injection.
More product information, including lot numbers and beyond use dates, can be found on FDA’s website.
Source: FDA
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
